Fact based stock research
Haemonetics (NYSE:HAE)

US4050241003

Haemonetics stock research in summary

haemonetics.com


Haemonetics shares have a market-typical stock price level. While they are good value, they are riskily financed, and show below average growth. We recommend evaluating whether the future of the company Haemonetics is typical for this industry which the market average price level of the shares suggests. If you believe that the future of the company is above average, that could be an argument for buying the shares and vice versa.


Latest Obermatt Ranks


Country USA
Industry Health Care Supplies
Index D.J. US Medical Equipment, S&P MIDCAP
Size class Large

September 3, 2021. Stock data may be delayed. Login to get the most recent research.


Achievements

Top 10 Stock


Stock analysis by the purely financial fact-based Obermatt Method for the investment strategies Value, Growth and Safety for Haemonetics from September 3, 2021.

We invest in our stock tips ourselves and openly publish the returns of our portfolio. That's how much we believe in our stock research. Subscribe to the top 10 stocks for 100 markets conveniently by e-mail.